Mechanisms of Resistance to Decitabine in the Myelodysplastic Syndrome

PURPOSE: The DNA methylation inhibitor 5-aza-2′-deoxycytidine (DAC) is approved for the treatment of myelodysplastic syndromes (MDS), but resistance to DAC develops during treatment and mechanisms of resistance remain unknown. Therefore, we investigated mechanisms of primary and secondary resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Taichun, Castoro, Ryan, El Ahdab, Samih, Jelinek, Jaroslav, Wang, Xiaodan, Si, Jiali, Shu, Jingmin, He, Rong, Zhang, Nianxiang, Chung, Woonbok, Kantarjian, Hagop M., Issa, Jean-Pierre J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157379/
https://www.ncbi.nlm.nih.gov/pubmed/21858090
http://dx.doi.org/10.1371/journal.pone.0023372

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157379/
https://www.ncbi.nlm.nih.gov/pubmed/21858090
http://dx.doi.org/10.1371/journal.pone.0023372

Ejemplares similares